The safty and efficacy of G protein-biased agonist oliceridine treatment in post operative pain management of VATS.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082913

Enrollment

Unknown

Registered

2024-04-10

Start date

2024-04-10

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain

Interventions

Group oliceridine(Group A):Controlled analgesia was performed with oliceridine

Group hydromorphone(Group H):Controlled analgesia was performed with hydromorphone

Group butorphanol (Group B):Controlled analgesia was performed with butorphanol

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Fully understand and voluntarily participate in this study, and sigh the informed consent form. 2.Undergoing elective thoracic surgery with VATS. 3.Subjects with ASA grades I-III. 4.Age between 18 and 70 years old (including the critical value),gender is not limited. 5.Body mass index is in the range of 18 to 30 kg/m2(including the critical value). 6.Ability to understand the research procedures and use the pain scales,and ability to communicate effectively with researchers. 7.Choose treatment in post operative pain.

Exclusion criteria

Exclusion criteria: 1.Refusing to participate in the study. 2.Known allergy to the study drug. 3Renal function or liver dysfunction. 4.Sleep apnea syndrome 5.Bronchial asthma. 6.Ischemic heart disease 7.Pulmonary heart disease 8.Active gastrointestinal ulcer or bleeding or inflammatory bowel disease, intestinal obstruction, etc 9.During pregnancy or lactation 10.Refusing PCIA 11.Patients with a pregnancy plan one month after surgery.

Design outcomes

Primary

Measure	Time frame
Achieving satisfactory analgesia with minimal emesis;	—

Secondary

Measure	Time frame
The incidence of moderate to severe pain;The supplementary of analgesic within 48h after surgery;Number of PCA presses;Patient satisfaction with analgesia;The incidence of chronic pain with 1 month after surgery;Incidence of PONV;Score of VAS;Vital sign;First exhaust time;Respiratory depression;Time of post-surgical off-bed activities;Score of sedation;Constipation;Itchy;Adverse reaction;Postoperative recovery quality;Hospitalization time;	—

Measure

Time frame

The incidence of moderate to severe pain;The supplementary of analgesic within 48h after surgery;Number of PCA presses;Patient satisfaction with analgesia;The incidence of chronic pain with 1 month after surgery;Incidence of PONV;Score of VAS;Vital sign;First exhaust time;Respiratory depression;Time of post-surgical off-bed activities;Score of sedation;Constipation;Itchy;Adverse reaction;Postoperative recovery quality;Hospitalization time;

—

Countries

China

Contacts

Public ContactLuo Tianyuan

Zunyi Medical University Affiliated Hospital

407542949@qq.com+86 185 8529 3669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026